BioMarin Pharma (BMRN) Posts Q4 Loss of $0.03/Share
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $64.52 +0.91%
Revenue Growth %: +31.4%
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: +31.4%
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 GAAP EPS of ($0.03), which may not compare to the analyst estimate of ($0.24). Revenue for the quarter came in at $353.2 million versus the consensus estimate of $377.35 million.
GUIDANCE:
BioMarin Pharma sees FY2019 revenue of $1.68-1.75 billion, versus the consensus of $1.73 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HP shares slide as tech giant forecasts 2027 PC market slump
- Super Micro Computer rises on AI server market optimism
- Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
